Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiviral drug
|
| gptkbp:approvalYear |
2006
|
| gptkbp:ATCCode |
gptkb:J05AF11
|
| gptkbp:brand |
gptkb:Sebivo
Tyzeka |
| gptkbp:CASNumber |
3424-98-4
|
| gptkbp:developedBy |
gptkb:Novartis
|
| gptkbp:eliminationHalfLife |
41 hours
|
| gptkbp:excretion |
renal
|
| gptkbp:hasMolecularFormula |
C10H14N2O5
|
| https://www.w3.org/2000/01/rdf-schema#label |
telbivudine
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
nucleoside analogue reverse transcriptase inhibitor
|
| gptkbp:metabolism |
not significantly metabolized
|
| gptkbp:pregnancyCategory |
B (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
fatigue headache increased creatine kinase |
| gptkbp:usedFor |
chronic hepatitis B
|
| gptkbp:bfsParent |
gptkb:hepatitis_B_virus
|
| gptkbp:bfsLayer |
6
|